Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Jul 01, 2022 11:17am
229 Views
Post# 34796229

June 30 ... What's Next !!!

June 30 ... What's Next !!!
https://www.nbcnews.com/health/health-news/fda-recommends-omicron-subvariants-ba4-ba5-fall-covid-boosters-rcna36125


Well once I read this news  attached .... I feel that our only hope right now is that Phizer is buying us out ...and the way it seems to sit with no real material news...web sites down...no contact with Rob or Salzman ..yet as low as sp is theres still some activity ....this is my reasoning....if our NO has the potential to truly relieve symptons of any said viruses of the Omicron family and save human lives...the close relationship innertwined with Phizer and where we were supposedly gonna have our Phase 1 ...that if to date we got a go ahead to start the phase 1 because of recent studies...why wouldnt Phizer be interested in us and in a different approach booster shot...especially since the past good few months that the Omicron variants 4 and 5 have become dominant and knowing the past vaccines have wained over time and needs amping up...then would explain no contact to Farrell and why he cannot purchase shares or invest in the Phase 1 at this time...yes I have ventured over to Drew's site and after reading his recent response ...wanted to share my last thoughts about this company...not trying to get anyones hopes up or excited...I just don't think that all the effort put forward todate with testing ..finding a location to run clinical trial and public positive NR from various feeds plus 2 new investors was to simply a second time to show up as a huge failure....just would not look good on future resumes...and both Farrell and Salzman  have public forms on big platforms you can reach with a public post...this is just IMO ....glta ...we should soon find out ?
<< Previous
Bullboard Posts
Next >>